Manufacturing and royalty revenues from RISPERDAL CONSTA
, INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA were $91.9 million, compared to $85.2 million for the same period in the prior year.
6,667,061, arising from the defendants' filing of an NDA with the FDA seeking approval to market defendants' extended release risperidone injections before the expiration patent protection on Risperdal Consta
. Alkermes and Janssen asked for a permanent injunction restraining and enjoining Luye against the commercial manufacture, use, offer for sale, sale in, and/or importation into the U.S.
(2) Although risperidone is one of the more widely used antipsychotics for treating schizophrenia, until recently the only available LAI preparation, risperidone microspheres (Risperdal Consta
), required 3 weeks of oral coverage upon initiation.
They were 69% less likely to die while on risperidone LAI (Risperdal Consta
), and 77% less likely to die while taking oral aripiprazole (Abilify).
Sales are then expected to decline between 2017 and 2023 due to the generic erosion of various brands including Otsuka's Abilify, Pfizer's Zeldox, Allergan's Saphris, and Janssen's Risperdal Consta
sales were down 18% to $254 million.
"We seem to be facing a situation where patients have a branded medication like Risperdal Consta
and no psychosocial treatment," he said.
29 March 2011 - Janssen EMEA, a company of US Johnson & Johnson (NYSE: JNJ), said last Friday that new data from an independent prospective study presented at the 19th European Congress of Psychiatry (EPA 2011) shows treatment with Risperdal Consta
(risperidone long-acting injection (RLAI)) is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.
Such products include parenteral sustained-release depots such as Risperdal Consta
(risperidone), Zyprexa Relprevv (olanzapine pamoate), Vivitrol (naltrexone) and Invega Sustenna (paliperidone palmitate).
Waikato DHB psychiatrist Wayne Miles outlined his study of the use of Risperdal Consta
medication in a Polynesian population.
Johnson & Johnson (New Brunswick NJ) said it failed to win approval to market Risperdal Consta
as a maintenance treatment to curb mood episodes in bipolar disorder patients with frequent relapses.
The company's lead commercial product, Risperdal Consta
[(risperidone) long- acting injection], is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned subsidiary of Johnson & Johnson.